Stellar Biotechnologies, Inc. has appointed Michael R. McClurg to VP, Business Development & Marketing. His employment begins shortly, and Company Executive VP, Darrell Brookstein's title will be changed to Executive VP, Corporate Development & Finance.
Darrell Brookstein said, "Stellar is very pleased to bring aboard a biotech and pharmaceutical executive with Michael's strong, commercial market accomplishments in the areas of vaccine, pharmaceutical and medical diagnostic product development. With broad-based operational expertise with both start-ups and mature companies, Michael will add valuable project management, strategic marketing and licensing/partnering skills to the Stellar team. Working closely with both CEO, Frank Oakes, and me, Michael will immediately interact with current and potential customers on the vaccine side and work with the regulatory group on market development and launch of our preclinical diagnostic product, which is expected to come to market in the very near term. We look for him to help us increase shareholder value and continue to build on Stellar's history of success."
Michael has over 25 years of technical and business experience in the biotechnology and pharmaceutical industries. He received his BS in Biology from the University of California, San Diego and an MBA from the University of San Diego. Michael has recently served as VP, Business Development & Strategic Marketing at Chemtron Biotech, a Shanghai-based medical diagnostic manufacturing organization.
Previously as VP, Business Development at Quidel Corporation, he was responsible for business development and strategic planning activities for Point-of-Care Diagnostics. Prior to joining Quidel, Michael served in a senior capacity at Maxim Pharmaceuticals, an oncology drug research and development organization.
He has fulfilled senior business and marketing management roles in drug development companies such as Ligand Pharmaceuticals, Isis Pharmaceuticals and Prometheus Laboratories.
Mr. McClurg said, "I am excited by the opportunity to take the lead in coordinating and executing Stellar's business development and marketing plan. While we will initially focus on strengthening and expanding the market for Stellar's current KLH products and product line, a significant effort will be devoted to developing Stellar's preclinical diagnostic products. The potential for Stellar's diagnostic approach is substantial and I look forward to helping realize this aspect of the business. I am also equally excited with longer term efforts to identify and develop new applications and uses for Stellar's proprietary methods, technologies and other products."